Antitumor activity of afatinib in EGFRT790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis
Favorite
Share
More Options
16

Open in WPS to view all 16 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
